Radiation dosimetry of the translocator protein ligands [18F]PBR111 and [18F]PBR102.
BACKGROUND
The translocator protein (TSPO) ligands [18F]PBR111 and [18F]PBR102 show promise for imaging neuroinflammation. Our aim was to estimate the radiation dose to humans from primate positron emission tomography (PET) studies using these ligands and compare the results with those obtained from studies in rodents.


METHODS
[18F]PBR111 and [18F]PBR102 PET-computed tomography studies were carried out in baboons. The cumulated activity in the selected source organs was obtained from the volume of interest time-activity curves drawn on coronal PET slices and adjusted for organ mass relative to humans. Radiation dose estimates were calculated in OLINDA/EXM Version 1.1 from baboon studies and compared with those calculated from Sprague-Dawley rat tissue concentration studies, also adjusted for relative organ mass.


RESULTS
In baboons, both ligands cleared rapidly from brain, lung, kidney and spleen and more slowly from liver and heart. For [18F]PBR111, the renal excretion fraction was 6.5% and 17% for hepatobiliary excretion; for [18F]PBR102, the renal excretion was 3.0% and 15% for hepatobiliary excretion. The estimated effective dose in humans from baboon data was 0.021 mSv/MBq for each ligand, whilst from rat data, the estimates were 0.029 for [18F]PBR111 and 0.041 mSv/MBq for [18F]PBR102.


CONCLUSIONS
Biodistribution in a nonhuman primate model is better suited than the rat model for the calculation of dosimetry parameters when translating these ligands from preclinical to human clinical studies. Effective dose calculated from rat data was overestimated compared to nonhuman primate data. The effective dose coefficient for both these TSPO ligands determined from PET studies in baboons is similar to that for [18F]FDG.
Department of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia. jordan@nucmed.rpa.cs.nsw.gov.au
Jordan D
JD
Verschuer
Jocelyn
J
Towson
Stefan
S
Eberl
Andrew
A
Katsifis
David
D
Henderson
Peter
P
Lam
Lingfeng
L
Wen
Christian
C
Loc'h
Filomena
F
Mattner
Sally
S
Thomson
Armin
A
Mohamed
Michael J
MJ
Fulham
D000818:Animals; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000378:metabolism*; D008024:Ligands; D008297:Male; D064847:Multimodal Imaging; D010215:Papio; D049268:Positron-Emission Tomography; D011725:Pyridines / Q000378:metabolism*; D011874:Radiometry; D051381:Rats; D011963:Receptors, GABA-A / Q000378:metabolism*; D014057:Tomography, X-Ray Computed
C576229:2-(6-chloro-2-(4-(2-fluoroethoxy)phenyl)imidazo(1,2-a)pyridin-3-yl)-N,N-diethylacetamide; C550561:2-(6-chloro-2-(4-(3-fluoropropoxy)phenyl)imidazo(1,2-a)pyridin-3-yl)-N,N-diethylacetamide; D007093:Imidazoles; D008024:Ligands; D011725:Pyridines; D011963:Receptors, GABA-A